Didik Indiarso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Didik Indiarso has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Cecilia Oktaria Permatadewi
Division of Gastroentero-Hepatology, Internal Medicine Department, Faculty of Medicine Diponegoro University, Kariadi Hospital, Semarang 50244, Indonesia
1 shared publication - Hery Djagat Purnomo
Gastroenterohepatology Division, Department of Internal Medicine, Dr. Kariadi Hospital, Faculty of Medicine, Universitas Diponegoro, Semarang 50244, Indonesia
1 shared publication - Hesti Triwahyu Hutami
Division of Gastroentero-Hepatology, Internal Medicine Department, Faculty of Medicine Diponegoro University, Kariadi Hospital, Semarang 50244, Indonesia
1 shared publication - Muflihatul Muniroh
Department of Physiology, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
1 shared publication
Latest Publications
- Open Access
- 17 February 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (4) , 2111
Diagnostic Value of microRNA Signatures for Early and Non-Invasive Detection of Colorectal Cancer: A Systematic Review and Meta-Analysis
Colorectal cancer (CRC) continues to be a primary contributor to the global health burden, and early detection is vital for optimal outcomes. Standard detection techniques, including colonoscopy and fecal occult blood tests, have been confirmed effective yet their invasiveness and poor sensitivity are a limitation. MicroRNA (miRNA) are now recognized as stable non-invasive biomarkers with differential expression in cancerous tissues, but reports have been heterogeneous and studied under different settings. This study, completed based on PRISMA guidelines, was a systematic review of miRNA signature diagnostic accuracy to detect early CRC. Case-case control studies, cross-sectional, and cohort research published between 2014–2024 were identified through the Scopus, PubMed, and Cochrane databases. We extracted diagnostic metrics such as sensitivity and specificity while assessing bias with the ROBINS-e tool and the Newcastle-Ottawa Scale. Meta-analyses showed that miRNA panels have high diagnostic accuracy with a pooled sensitivity of 1.84 (95% CI: 1.48–2.19) and a pooled specificity of 1.43 (95% CI: 1.01–1.85). The accuracy of miRNA-139-3p was the highest among all panels. Meta-regression did not reveal any significant confounders, while publication bias was not detected. These results highlight the miRNA panels’ potential as non-invasive biomarkers in early CRC detection, providing a promising alternative to conventional screening methods, with miRNA-139-3p as the most diagnostically accurate biomarker.
- 17 February 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (4) , 2111
Open AccessDiagnostic Value of microRNA Signatures for Early and Non-Invasive Detection of Colorectal Cancer: A Systematic Review and Meta-Analysis
Colorectal cancer (CRC) continues to be a primary contributor to the global health burden, and early detection is vital for optimal outcomes. Standard detection techniques, including colonoscopy and fecal occult blood tests, have been confirmed effective yet their invasiveness and poor sensitivity are a limitation. MicroRNA (miRNA) are now recognized as stable non-invasive biomarkers with differential expression in cancerous tissues, but reports have been heterogeneous and studied under different settings. This study, completed based on PRISMA guidelines, was a systematic review of miRNA signature diagnostic accuracy to detect early CRC. Case-case control studies, cross-sectional, and cohort research published between 2014–2024 were identified through the Scopus, PubMed, and Cochrane databases. We extracted diagnostic metrics such as sensitivity and specificity while assessing bias with the ROBINS-e tool and the Newcastle-Ottawa Scale. Meta-analyses showed that miRNA panels have high diagnostic accuracy with a pooled sensitivity of 1.84 (95% CI: 1.48–2.19) and a pooled specificity of 1.43 (95% CI: 1.01–1.85). The accuracy of miRNA-139-3p was the highest among all panels. Meta-regression did not reveal any significant confounders, while publication bias was not detected. These results highlight the miRNA panels’ potential as non-invasive biomarkers in early CRC detection, providing a promising alternative to conventional screening methods, with miRNA-139-3p as the most diagnostically accurate biomarker.